Selective Binding of Cyclodextrins with Leflunomide and Its Pharmacologically Active Metabolite Teriflunomide
- PMID: 33265979
- PMCID: PMC7730839
- DOI: 10.3390/ijms21239102
Selective Binding of Cyclodextrins with Leflunomide and Its Pharmacologically Active Metabolite Teriflunomide
Abstract
The selectivity of encapsulation of leflunomide and teriflunomide by native α-, β- and γ-cyclodextrins was investigated through 1H NMR and molecular modeling. Thermodynamic analysis revealed the main driving forces involved in the binding. For α-cyclodextrin, the partial encapsulation was obtained while deep penetration was characterized for the other two cyclodextrins, where the remaining polar fragment of the molecule is located outside the macrocyclic cavity. The interactions via hydrogen bonding are responsible for high negative enthalpy and entropy changes accompanying the complexation of cyclodextrins with teriflunomide. These results were in agreement with the molecular modeling calculations, which provide a clearer picture of the involved interactions at the atomic level.
Keywords: complex formation; cyclodextrin; leflunomide; molecular modeling; selectivity; teriflunomide.
Conflict of interest statement
The authors declare no conflict of interest.
Figures







Similar articles
-
Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.Curr Comput Aided Drug Des. 2021;17(3):480-491. doi: 10.2174/1573409916666200527133126. Curr Comput Aided Drug Des. 2021. PMID: 32459610
-
On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.J Mol Model. 2015 May;21(5):105. doi: 10.1007/s00894-015-2643-z. Epub 2015 Apr 8. J Mol Model. 2015. PMID: 25851105 Free PMC article.
-
γ-Cyclodextrin-metal organic frameworks as efficient microcontainers for encapsulation of leflunomide and acceleration of its transformation into teriflunomide.Carbohydr Polym. 2019 Jul 15;216:224-230. doi: 10.1016/j.carbpol.2019.04.037. Epub 2019 Apr 9. Carbohydr Polym. 2019. PMID: 31047061
-
Leflunomide nanocarriers: a new prospect of therapeutic applications.J Microencapsul. 2024 Dec;41(8):715-738. doi: 10.1080/02652048.2024.2407373. Epub 2024 Sep 25. J Microencapsul. 2024. PMID: 39320955 Review.
-
Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.Expert Rev Clin Pharmacol. 2015 May;8(3):315-20. doi: 10.1586/17512433.2015.1019343. Epub 2015 Feb 24. Expert Rev Clin Pharmacol. 2015. PMID: 25712857 Review.
Cited by
-
The Physical Chemistry and Chemical Physics (PCCP) Section of the International Journal of Molecular Sciences in Its Publications: The First 300 Thematic Articles in the First 3 Years.Int J Mol Sci. 2021 Dec 27;23(1):241. doi: 10.3390/ijms23010241. Int J Mol Sci. 2021. PMID: 35008667 Free PMC article.
-
DFT Study of Interaction between Teriflunomide and β-cyclodextrin.Curr Mol Med. 2025;25(2):187-201. doi: 10.2174/0115665240270161231112120838. Curr Mol Med. 2025. PMID: 38243924
References
-
- Warnke C., Stüve O., Kieseiera B.C. Teriflunomide for the treatment of multiple sclerosis. Clin. Neurol. Neurosurg. 2013;115S:511–514. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources